Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q3SXM5
UPID:
HSDL1_HUMAN
Alternative names:
Short chain dehydrogenase/reductase family 12C member 3
Alternative UPACC:
Q3SXM5; B4DSL2; D3DUL4; Q3SXM4; Q8NC98; Q9BY22
Background:
Inactive hydroxysteroid dehydrogenase-like protein 1, also known as Short chain dehydrogenase/reductase family 12C member 3, represents a unique entity within the enzyme classification. Despite its name suggesting an inactive status, the protein's structural features and evolutionary conservation hint at potential roles in cellular processes.
Therapeutic significance:
Understanding the role of Inactive hydroxysteroid dehydrogenase-like protein 1 could open doors to potential therapeutic strategies. Its exploration is pivotal in unveiling novel pathways for drug discovery and development.